Total Payments
$612,959
2023 Payments
$5,716
Companies
13
Transactions
168
Medicare Patients
1,799
Medicare Billing
$81,971
Payment Breakdown by Category
Research$338,551 (55.2%)
Consulting$253,350 (41.3%)
Travel$11,997 (2.0%)
Other$8,476 (1.4%)
Food & Beverage$585.64 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $338,551 | 30 | 55.2% |
| Consulting Fee | $253,350 | 117 | 41.3% |
| Travel and Lodging | $11,997 | 11 | 2.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,250 | 1 | 1.3% |
| Food and Beverage | $585.64 | 7 | 0.1% |
| Entertainment | $226.22 | 2 | 0.0% |
Payments by Type
Research
$338,551
30 transactions
General
$274,408
138 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie, Inc. | $320,363 | 25 | $0 (2019) |
| GlaxoSmithKline, LLC. | $119,330 | 81 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $44,832 | 8 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $33,504 | 8 | $0 (2023) |
| Boehringer Ingelheim International GmbH | $25,462 | 13 | $0 (2022) |
| AstraZeneca UK Limited | $15,858 | 4 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $14,694 | 13 | $0 (2019) |
| Novo Nordisk AS | $14,063 | 5 | $0 (2021) |
| PFIZER INC. | $9,472 | 4 | $0 (2020) |
| Resmed Corp | $6,601 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $5,716 | 2 | Amgen Inc. ($3,016) |
| 2022 | $6,858 | 4 | AstraZeneca Pharmaceuticals LP ($3,525) |
| 2021 | $10,600 | 7 | GlaxoSmithKline, LLC. ($4,675) |
| 2020 | $96,191 | 45 | GlaxoSmithKline, LLC. ($47,675) |
| 2019 | $101,686 | 57 | GlaxoSmithKline, LLC. ($49,355) |
| 2018 | $191,348 | 30 | AbbVie, Inc. ($134,518) |
| 2017 | $200,561 | 23 | AbbVie, Inc. ($175,608) |
All Payment Transactions
168 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/18/2023 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $3,016.00 | General |
| 05/24/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 12/21/2022 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 10/01/2022 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $33.07 | General |
| 07/01/2022 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 02/20/2022 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,525.00 | General |
| 06/23/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 05/25/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 04/12/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| 02/05/2021 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 01/26/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $925.00 | General |
| 01/26/2021 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 01/06/2021 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Diabetes | ||||||
| 12/23/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,225.00 | General |
| 12/21/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| 12/06/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $7,425.00 | General |
| 11/16/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 11/16/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,025.00 | General |
| 10/26/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| 10/23/2020 | Novo Nordisk AS | — | — | Cash or cash equivalent | $2,812.50 | Research |
| Study: EX9536-4665 | ||||||
| 10/21/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,100.00 | General |
| 10/21/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 09/22/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 09/22/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 09/22/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M11-352 | AbbVie, Inc. | $320,101 | 21 |
| EX9536-4665 | Novo Nordisk AS | $11,813 | 4 |
| CAT-PEF | Resmed Corp | $6,375 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 425 | 433 | $99,921 | $19,301 |
| 2022 | 5 | 425 | 438 | $97,997 | $18,786 |
| 2021 | 5 | 440 | 443 | $100,505 | $20,275 |
| 2020 | 5 | 509 | 523 | $98,808 | $23,609 |
Total Patients
1,799
Total Services
1,837
Medicare Billing
$81,971
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 282 | 289 | $74,851 | $13,997 | 18.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $6,358 | $1,679 | 26.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 26 | 26 | $7,630 | $1,493 | 19.6% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Facility | 2023 | 27 | 27 | $6,804 | $1,285 | 18.9% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 24 | 25 | $2,275 | $472.75 | 20.8% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 27 | 27 | $1,431 | $265.75 | 18.6% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 22 | 22 | $572.00 | $108.40 | 19.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 297 | 309 | $80,031 | $15,363 | 19.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 30 | 30 | $7,770 | $1,545 | 19.9% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Facility | 2022 | 20 | 20 | $5,040 | $863.71 | 17.1% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2022 | 38 | 39 | $3,549 | $741.30 | 20.9% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2022 | 21 | 21 | $1,113 | $189.81 | 17.1% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2022 | 19 | 19 | $494.00 | $83.50 | 16.9% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2021 | 307 | 310 | $80,290 | $16,130 | 20.1% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 40 | 40 | $10,360 | $2,157 | 20.8% |
| 93350 | Ultrasound examination of the heart performed during rest, exercise, and/or drug-induced stress with interpretation and report | Facility | 2021 | 24 | 24 | $6,048 | $1,214 | 20.1% |
| 93308 | Follow-up or limited ultrasound examination of heart | Facility | 2021 | 21 | 21 | $1,911 | $405.69 | 21.2% |
| 93018 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician interpretation and report | Facility | 2021 | 24 | 24 | $1,272 | $245.51 | 19.3% |
| 93321 | Follow-up or limited heart doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2021 | 24 | 24 | $624.00 | $122.33 | 19.6% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2020 | 348 | 355 | $78,225 | $19,145 | 24.5% |
| 93350 | Ultrasound examination of the heart performed during rest, exercise, and/or drug-induced stress with interpretation and report | Facility | 2020 | 32 | 32 | $7,684 | $1,570 | 20.4% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2020 | 27 | 27 | $6,433 | $1,492 | 23.2% |
| 93308 | Follow-up or limited ultrasound examination of heart | Facility | 2020 | 42 | 49 | $4,149 | $919.13 | 22.2% |
| 93018 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician interpretation and report | Facility | 2020 | 31 | 31 | $1,529 | $325.81 | 21.3% |
| 93321 | Follow-up or limited heart doppler ultrasound study of heart blood flow, valves, and chambers | Facility | 2020 | 29 | 29 | $788.00 | $157.83 | 20.0% |
About Dr. Dalane Kitzman, MD
Dr. Dalane Kitzman, MD is a Cardiovascular Disease healthcare provider based in Winston Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1396720678.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dalane Kitzman, MD has received a total of $612,959 in payments from pharmaceutical and medical device companies, with $5,716 received in 2023. These payments were reported across 168 transactions from 13 companies. The most common payment nature is "" ($338,551).
As a Medicare-enrolled provider, Kitzman has provided services to 1,799 Medicare beneficiaries, totaling 1,837 services with total Medicare billing of $81,971. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Winston Salem, NC
- Active Since 12/09/2005
- Last Updated 05/12/2008
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1396720678
Products in Payments
- Non-Covered $44,832
- PRADAXA (Drug) $13,087
- AirCurve (Device) $6,375
- MK-1242 (Drug) $6,001
- ENTRESTO (Drug) $3,565
- FARXIGA (Drug) $3,150
- ApneaLink (Device) $226.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Winston Salem
Mark Mitchell, Md, MD
Cardiovascular Disease — Payments: $87,413
Cardiovascular Disease $87,413
Dr. Nizar Noureddine, M.d, M.D
Cardiovascular Disease — Payments: $62,885
Cardiovascular Disease $62,885
Charles Harris, Md, MD
Cardiovascular Disease — Payments: $43,442
Cardiovascular Disease $43,442
Dr. Samuel Turner, M.d, M.D
Cardiovascular Disease — Payments: $42,986
Cardiovascular Disease $42,986
Michael Drucker, Md, MD
Cardiovascular Disease — Payments: $41,438
Cardiovascular Disease $41,438
Dr. Rafael Cavalcanti, M.d, M.D
Cardiovascular Disease — Payments: $33,643
Cardiovascular Disease $33,643